To assess BCL-2 as a marker of proliferative activity in AML subgroups, we compared the degree of leukocytosis, as well as the presence/absence of peripheral blasts, between the BCL-2− and BCL-2+ subgroups. This evidence concerns the gene BCL2 and acute myeloid leukemia.